Nathan Weinstein
Stock Analyst at Aegis Capital
(0.27)
# 4,239
Out of 4,944 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.33 | +5,915.04% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.45 | +3,233.33% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.62 | +867.74% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.83 | +4,120.43% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.70 | +122.22% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.12 | +1,315.09% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $7.60 | +31.58% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $18.90 | +159.26% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.08 | +13,788.89% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.68 | +58,595.65% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $0.96 | +3,031.52% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.33 | +651.88% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $63.25 | +152.96% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $30.89 | +81.29% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $4.05 | +566.67% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.85 | +4,041.52% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.91 | +528.27% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $11.92 | +529.19% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $3.03 | +2,804.29% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.93 | +6,043.34% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $3.21 | +4,105.61% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.65 | +110.53% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $14.90 | +1,376.51% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $3.00 | +183.33% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.33
Upside: +5,915.04%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.45
Upside: +3,233.33%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.62
Upside: +867.74%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.83
Upside: +4,120.43%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.70
Upside: +122.22%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.12
Upside: +1,315.09%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $7.60
Upside: +31.58%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $18.90
Upside: +159.26%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.08
Upside: +13,788.89%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.68
Upside: +58,595.65%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $0.96
Upside: +3,031.52%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.33
Upside: +651.88%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $63.25
Upside: +152.96%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $30.89
Upside: +81.29%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $4.05
Upside: +566.67%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.85
Upside: +4,041.52%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $1.91
Upside: +528.27%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $11.92
Upside: +529.19%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $3.03
Upside: +2,804.29%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.93
Upside: +6,043.34%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $3.21
Upside: +4,105.61%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.65
Upside: +110.53%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $14.90
Upside: +1,376.51%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $3.00
Upside: +183.33%